Skip to main content
. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193

Fig 3. Validation of genomic markers of chemosensitivity in the TCGA triple negative breast cancer cohort.

Fig 3

(A) Somatic and germline mutations in AR/FOXA1 pathway and CMB in the TCGA TNBC cohort. (B) Kaplan-Meier estimator of overall survival outcomes by AR/FOXA1 mutational status. Tumors carrying at least one mutation in the AR/FOXA1 pathway had significantly better overall survival compared to WT tumors (log-rank test, p = 0.028). (C) Overall survival outcomes of TCGA TNBC cases by CMB category. Cases with high CMB have significantly better overall survival (log-rank test, p = 0.025). AR, androgen receptor; CMB, clonal mutation burden; TCGA, The Cancer Genome Atlas; TNBC, triple negative breast cancer; WT, wild-type.